Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus: A Randomized Clinical Trial
Key Findings
The study found that early use of mycophenolate mofetil (MMF) alongside prednisone and hydroxychloroquine sulfate reduced the risk of severe flare and incidence of lupus nephritis in patients with new-onset systemic lupus erythematosus (SLE) and a high titer of anti-double-stranded DNA (dsDNA) antibody without major organ involvement.
Study Details
The trial enrolled 130 treatment-naive patients aged 18 to 65 years in China and compared the efficacy and safety of MMF plus prednisone and hydroxychloroquine sulfate with prednisone and hydroxychloroquine sulfate alone over 96 weeks.
Practical Solutions
Clinical trials play a crucial role in developing safe treatments. Our AI-driven platform, DocSym, consolidates clinical protocols and research into an easily accessible knowledge base for clinicians, extending the benefits of clinical trials into everyday medical practice.
Streamlining operations is essential in today’s healthcare environment. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
Value
By leveraging AI, clinics can improve workflows, enhance patient outcomes, and reduce paper routines. Learn more about how we can help at aidevmd.com.